Eikon Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eikon Therapeutics, Inc. (EIKN) on August 3, 2026, covering the event date of July 31, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
Effective July 31, 2026, Leon Chen, Ph.D., and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. The Company explicitly stated that these resignations were not due to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items beyond the board departures noted above.
Key Facts for Investor Verification
- Leon Chen, Ph.D., and Joshua Wolfe resigned from the Board of Directors effective July 31, 2026.
- The resignations were not caused by disagreements with the Company.
- The report was signed by Alfred Bowie, Ph.D., Chief Financial Officer, on August 3, 2026.
- No financial data or operational updates are included in this specific filing.